Expanding the Scope of Precision Care for Patients With HR-Positive Breast Cancers: Things You Should Know

Download All
Learn from expert faculty as they discuss application of recent clinical evidence to develop personalized treatment plans for HR-positive/HER2-negative early and advanced breast cancer, the use of current and emerging oral targeted therapies and strategies to promote adherence with a downloadable slideset from a satellite symposium, an on-demand webcast, and expert commentary.
Komal Jhaveri, MD
Program Director
Erica Mayer, MD, MPH
Laura M. Spring, MD

ClinicalThought

Experts discuss key updates in hormone receptor–positive breast cancer, including recent data presented at ASCO 2022.

Komal Jhaveri, MD
Program Director
Erica Mayer, MD, MPH Laura M. Spring, MD
Released: July 18, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Lilly
Novartis Pharmaceuticals Corporation
Sanofi Genzyme

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings